inflammatory syndrome and suspicion of fever from digestive origin, associating amoxicillin and clavulanic acid was initiated and then replaced by cefotaxim (1 g three times a day, IV), ofloxacin (200 mg twice a day, per os) and metronidazole (500 mg three times a day, per os) from the 13 to 25 February. Amikacin (1 g per day, IV) was added from the 13 to 18
February. The antibiotic treatment was modified for ciprofloxacin (400 mg twice a day, IV) on 26 February. Piperacillin-tazobactam (4 g four times a day, IV, 28 February to 05 March) and gentamycin (80 mg twice a day, IV, 26 to 27 February) were also added. On 28 February, the patient was transferred to an intensive care unit for respiratory decompensation. Proton pump inibitors (pantoprazole, 20 mg per day and esomeprazole, 40 mg twice a day) were also given successively from the 12 February until the patient was discharged on 29 April. The patient with improved clinical outcome was transferred again to gastroenterology ward on 5
March and antibiotics were stopped on 16 March. On 21 March, the expectoration was positive to Candida albicans and due to loss of body weight and condition, fluconazole was given to the patient. A colitis due to C. difficile was diagnosed 8 days later, on 29 March using the Meridian tox A/B assay and the specific culture medium CLO (Biomérieux). The patient was treated by metronidazole 250 mg four times a day for 2 days and then by metronidazole 500 mg three times a day, per os for 13 days. Diarrhea resolved on 1 st April.
The patient did not present recurrence. bowel movements per day). The C-reactive protein value was 276 mg/L. C. difficile infection was diagnosed on 3 June using stool cytotoxicity assay and toxigenic culture and was treated by metronidazole (500 mg twice a day for 10 days (7 June to 16 June) given by nasogastric tube. On 2 June, worsening respiratory symptoms were observed and pneumocystose was diagnosed: trimethoprim/sulfamethoxazole and voriconazole were started. On 17 June the patient is discharged to palliative care.
CD10-165 strain was isolated from a patient admitted in Villefranche-sur-Saône hospital, Villefranche-sur-Saône, France on 13 July 2010. This 74 old-year man was previously hospitalized from 19 March to 8 April for acute decompensated heart failure due to erysipelas treated by amoxicillin 1 g three times a day for 14 days. This patient was also treated by rabeprazole (10 mg per day). After discharge, the patient was hospitalized again on 20 May in pneumology for decompensation of chronic obstructive pulmonary disease. The patient was treated with prednisolone (60 mg to 20 mg). After discharge, the patient presented with diarrhea and asthenia which led to a third hospitalization of the patient on 13 July. Patient was treated with amoxicillin and clavulanic acid (1 g three times a day) for an infectious syndrome and decompensation of chronic obstructive pulmonary disease. On admission the patient was febrile (37.8°C), the C-reactive protein value was 184 mg/L, white blood cell count was 25 000/mm 3 , the lactate value was 0.9 mmol/L and the creatinine value was 118 µmol/L. The day after the patient worsened, his abdomen was distended and diarrhea was abundant. The Creactive protein, the white blood cell count, the lactate and creatinine values increased to 298 mg/L, 51 000/mm 3 , 10 mmol/L and 175 µmol/L, respectively. The scanner performed showed a peritoneal effusion with a thickening aspect of the sigmoid and the colon. A colostomy was performed and pseudomembrans were found. The patient deceased on 14 July in a context of a multiple organ failure and shock. The immune-enzymatic test (Immunocard, Meridian) performed on 15 July was positive for the toxins A/B in a stool sample. The death was directly attributed to C. difficile. 
